Trial Profile

Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 19 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucidinostat (Primary) ; Paclitaxel; Trastuzumab
Indications Adenocarcinoma; Advanced breast cancer
Focus Adverse reactions
Sponsors HUYA Bioscience International

Most Recent Events

14 Jul 2022 Planned End Date changed from 1 Sep 2016 to 2 Dec 2015.
14 Jul 2022 Planned primary completion date changed from 1 Jun 2016 to 2 Dec 2015.
08 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com